Published in final edited form as:

Anesthesiology. 2003 February ; 98(2): 474–484.

Nociception in Persistent Pancreatitis in Rats:

Effects of Morphine and Neuropeptide Alterations

Louis P. Vera-Portocarrero, B.S.^{*}, Ying Lu, M.D.[†], and Karin N. Westlund, Ph.D.[‡]

Abstract

Background—Most animal models of pancreatitis are short-lived or very invasive. A noninvasive animal model of pancreatitis developed in highly inbred rats by Merkord *et al.* with symptoms persisting for 3 weeks was adopted in the current study to test its validity as a model of visceral pain in commercially available rats.

Methods—The persistent pancreatitis model was established by tail vein injection of dibutyltin dichloride. Animals were given 10% alcohol in their drinking water to enhance the pancreatitis attack. Blood serum pancreatic enzymes and nociceptive state were monitored for 3 weeks after dibutyltin dichloride or vehicle. Behavioral testing included reflexive withdrawal to mechanical and thermal stimulation of the abdominal area. The effect of morphine on nociceptive behaviors was tested. Histologic analysis of the pancreas and immunohistochemical analysis of substance P and calcitonin gene-related peptide in the spinal cord are included in the study.

Results—Compared with naïve and vehicle-only injected control groups, rats receiving dibutyltin dichloride demonstrated an increase in withdrawal events after von Frey stimulation and decreased withdrawal latency after thermal stimulation, signaling a sensitized nociceptive state through 7 days. These pain-related measures were abrogated by morphine. Blood serum concentrations of amylase and lipase as well as tissue inflammatory changes and substance P were also significantly elevated during this same time period.

Conclusions—These results indicate that animals with the dibutyltin dichloride-induced experimental pancreatitis expressed serum, histologic, and behavioral characteristics similar in duration to those present during acute attacks experienced by patients with chronic pancreatitis. These findings and responsivity to morphine suggest the utility of this model developed in a commercially available strain of rats for study of persistent visceral pain.

VISCERAL pain is frequently resistant to treatment by physicians, as in persons with chronic pancreatitis or pancreatic cancer.¹ Pain is the only sensation that can be elicited from the pancreas and occurs when the pancreas is inflamed or during pancreatic cancer.² Animal models of acute pancreatitis are abundant, but they represent acute noxious stimulation of the pancreas that resolves after a finite and typically short amount of time.^{3–5} These models

Address reprint requests to Dr. Westlund: Department of Anatomy and Neurosciences, University of Texas Medical Branch, Medical Research Building, Room 10.138D, 301 University Boulevard, Galveston, Texas 77555-1043. kwhigh@utmb.edu.

^{*}Graduate Assistant.

[†]Assistant Professor.

[‡]Professor.

Individual article reprints are available through the Journal Web site, www.anesthesiology.org.

Presented at the 30th Annual meeting of the Society for Neuroscience, New Orleans, Louisiana, November 5, 2000.

are valuable for the study of the acute events, but a model of longer duration evoking central sensitization and pain⁶ is desirable for more clinically relevant study since it is likely that long-term changes are induced by the continuous barrage of noxious information from the periphery.

Nociceptive reflexive behaviors have been adopted as indicators of the pain state of an animal. Validation of specific behaviors is necessary in the establishment of animal models of painful conditions.⁷ It is also important to elucidate the neurochemical expression changes notable during the generation and maintenance of central changes leading to those behaviors for the purpose of identifying targets for possible pharmacologic interventions.

In the human condition, pain elicited from the pancreas is often “referred” to the upper (epigastric) abdominal area and radiates to the back.^{8,9} In human patients, these dermatomal areas are usually tender to touch (referred mechanical allodynia).⁹ In animal models, this phenomenon is also observed in rats, where visceral pain is characterized as a lowered threshold of response to mechanical stimulation of the abdominal areas. The abdominal areas are assumed to be zones of referred pain for the animal.^{10–12} In the current study we used these behavioral paradigms to test the development of nociceptive behaviors in animals with persistent pancreatic inflammation and to determine if these behaviors are responsive to morphine treatment as in the human condition.¹³ At the same time, we monitored pancreatic enzyme serum concentrations (amylase and lipase) as a clinical marker of pancreatitis.¹⁴

Neuropeptides known to be present in the afferent fibers innervating visceral organs have been characterized.^{15–17} Substance P (SP) and calcitonin gene-related peptide (CGRP) are found in the majority of fibers innervating the pancreas.^{18,19} Both SP and CGRP typically undergo dynamic changes in their expression during the induction and maintenance of pain states. During the development of monoarthritis, expression of SP and CGRP is increased.^{20,21} In models of peripheral somatic inflammation, SP and CGRP present a wide spectrum of plasticity at the spinal cord and dorsal root ganglion levels.^{22–24} In visceral pain studies, SP and CGRP content is decreased in colonic afferents after inflammation and released in the mouse colon after capsaicin,^{25,26} while in the spinal cord, SP and CGRP staining is increased after colon inflammation.²⁷ Elucidation of the expression changes that these neuropeptides undergo in this model of pancreatitis with persistent visceral pain are described here. A preliminary report of this study has been published in abstract form.²⁸

Materials and Methods

Induction of Pancreatitis

All experiments were approved by the University of Texas Medical Branch Animal Care and Use Committee and adhered to the guidelines of this committee as well as the policies on the Ethical Treatment of Research Animals published by the International Association for the Study of Pain. Male Lewis-inbred rats (Harlan, Indianapolis, IN) weighed between 150 and 200 g at the onset of the study. The animals were maintained under standard conditions with two rats per cage and given Teklab diet 8626. This diet is low in soybean oil and was preferred in this study since it has been shown that diets high in soybean isoelectin content can be antinociceptive.²⁹ Three experimental groups were compared in these studies,

including rats with persistent experimental pancreatitis (n = 8), vehicle injection (n = 8), or naïve controls (n = 6). Pancreatitis was induced in these animals according to a protocol reported by Sparmann *et al.*³⁰ The dibutyltin dichloride (DBTC) was dissolved first in 100% ethanol (two parts) and then mixed with glycerol (three parts). The DBTC (8 mg/kg body weight; Aldrich Co., Milwaukee, WI) was injected into the tail vein of rats during methohexital anesthesia (40 mg/kg body weight) in a volume of 250 μ l solvent. For the control groups, the animal were naïve or the tail veins were injected with the vehicle (ethanol:glycerol, 2:3) only. The rationale for this vehicle-injected group is to control for any nonspecific effects of the vehicle solution itself. The DBTC and vehicle-injected groups were maintained on 10% ethanol in their drinking water throughout the experiment to provide enhancement of irritation to the pancreas according to Merkord *et al.*³¹ On days 3, 7, 10, 14, and 21, blood was drawn from the tail vein to measure clinical serum parameters indicative of pancreatitis (amylase and lipase blood concentrations). Amylase serum concentrations were assayed using the amylase infinity kit (Sigma, St. Louis, MO) with 4,6-ethylidene-(G7) p-nitrophenyl, D-maltoheptosid as the substrate. Lipase serum concentrations were assayed using the Lipase-PS kit (Sigma) with triolein as a substrate. Animals were transcardially perfused with para-formaldehyde for histologic and immunohistochemical procedures at each of the above mentioned time points.

Behavioral Procedures

Before mechanical and thermal sensitivity testing, all animals were environmentally acclimated to the clear Plexiglas cubicle testing apparatus for 4 h daily for 3 days. Baseline testing took place a day before induction of pancreatitis. Mechanical hypersensitivity in the abdominal area was quantified by measuring the number of withdrawal events (either abdominal withdrawal from the von Frey filament or consequent licking of the abdominal area, or whole body withdrawal) in response to normally innocuous or subthreshold mechanical stimuli.³² The stimuli, applied to the abdominal area, consisted of von Frey filaments with bending forces of 4.78 and 9.96 mN, which are considered subthreshold stimuli, and with a von Frey filament with bending force of 204.1 mN, used as a suprathreshold stimulus. In human perceptual terms, these mechanical forces represent a subthreshold stimulus, a light touch, and a poke, respectively.³³ To perform this test, rats were placed inside Plexiglas boxes on an elevated, fine fiberglass screen mesh and acclimated for 60 min before testing. The von Frey filaments were applied from underneath through the mesh floor, to the abdominal area at different points on the surface. A single trial consisted of 10 applications of von Frey filaments applied once every 10 s to allow the animal to cease any response and return to a relatively inactive position. It is unlikely that behavioral sensitization will occur with the testing interval of 10 s or more. The mean occurrence of withdrawal events in each of the trials was expressed as the number of responses of 10 applications, where 0 indicates no withdrawal and 10 indicates the maximum number of withdrawals. Three trials were performed in each animal, and the withdrawal events were averaged to obtain a single value per rat per time point.

Thermal hyperalgesia was measured by the latency of withdrawal to thermal stimuli in the noxious range as previously described by Bennet and Xie³⁴ and Hargreaves *et al.*³⁵ Animals were placed in Plexiglas boxes on an elevated glass plate through which a high-intensity

light beam was shone. A radiant heat stimulus was applied by concentrating a beam of light through a hole (1×1 cm) in the light box onto the abdominal area. The light beam and timer were immediately stopped when the animal withdrew, allowing the measurement of time between the start of the light beam and the withdrawal event. Pilot studies demonstrated that the abdominal skin of the rats is not separated from the glass surface more than 1 mm. These same pilot studies showed that the rate of heat increase within this distance does not vary significantly. Forty-five minutes was allowed between each trial, and three trials were averaged. A withdrawal event to radiant heat applied to the abdomen was defined as abdominal withdrawal (either abdominal musculature contraction or lifting of the abdomen through postural adjustment) accompanied by head turning toward the stimuli and licking of the abdominal area. The experimenter was blinded to the type of treatment that the animals had received.

Morphine Study

All three groups of rats ($n = 6$ per group) received either morphine sulfate (Paddock Laboratories, Minneapolis, MN) using a cumulative systemic dose regimen of 1, 5, and 10 mg/kg intraperitoneally (lower abdominal area) or saline vehicle every 30 min. Mechanical and thermal hypersensitivity was evaluated after each dose, ending with the last test 30 min after the last dose (cumulative, 10 mg/kg; 1.5 h after the first dose). The experimenter performing the behavioral tests was unaware of which animals had received either morphine or saline injection. The effectiveness of morphine on mechanical and thermal hypersensitivity in animals with pancreatitis was tested in comparisons with responses of animals injected only with vehicle solution. The scores for responses to the three individual von Frey filaments were totaled, and the single value was plotted for simplicity of presentation.

Histologic Procedures

Pancreatic tissues were removed before transcardial perfusion with paraformaldehyde, and the tissue was placed in several 0.1-M phosphate buffered saline (PBS, pH 7.4) washes to remove blood elements. After the washes, pancreatic tissue was placed in 4% paraformaldehyde for 3 h, subsequently diced into smaller pieces, and kept in the fixative solution for 2 days. The tissue was transferred through graded ethanol solutions (80%, 95%, and 100% twice each). Pancreatic tissue was then transferred to xylene washes twice and placed in crucibles with a solution of xylene and melted paraffin (50:50 $\times 2$), placed in 100% paraffin ($\times 2$), and placed the oven for 45 min (60°C). Tissue was placed in cassettes and embedded in paraffin. Paraffin blocks were cut in $8\text{-}\mu\text{m}$ sections and stained with hematoxylin and eosin. As a control for nonspecific effects of DBTC, liver tissue was also taken from these rats and processed in the same manner as described above. Methylene blue dye was injected transcardially into rats with pancreatic inflammation and control rats to establish sites of inflammation by gross visual inspection for plasma extravasation. The methylene blue (2%) was injected in four 1-ml boluses and allowed to circulate for 1 h before visual inspection.

Immunohistochemical Procedures

On days 3, 7, 14, and 21 after tail vein injection, Lewis rats from all three groups (naive, vehicle, and DBTC-treated, $n = 4$ per group per time point) were perfused, and the thoracic segments of the spinal cords were removed and processed for immunohistochemistry. Rats were perfused transcardially with 50 ml of heparinized saline at 37°C followed by 500 ml of cold (4°C) 4% paraformaldehyde solution (pH 7.4). The spinal cords were removed carefully and postfixed in 4% paraformaldehyde solution at room temperature for 4 h before cryoprotection and storage in 30% sucrose–phosphate buffer solution overnight. The T6–T10 segments of the spinal cord were embedded in OCT cryoprotectant compound (Allegiance Healthcare Corp., Torrance, CA) and stored at –70°C until processed. Tissue blocks were cut in 30- μ m-thick coronal sections on a freezing sliding microtome, and alternate sections were collected in PBS (pH 7.4). The free-floating sections were rinsed six times in the PBS used as the diluent buffer (0.1 M PBS) throughout the procedure before immersion in 3% normal goat serum–triton 100-X for 30 min at room temperature. The sections were incubated in either rabbit anti-SP (1:30,000; Incstar, Stillwater, MN) or rabbit anti-CGRP (1:5000; Peninsula, Belmont, CA) for 24 h, after which sections were rinsed in PBS and incubated in goat anti-rabbit immunoglobulin G (1:200, Vector Inc., Burlingame, CA) for 2 h. After rinsing in PBS, the sections were incubated in ExtrAvidin-Peroxidase–PBS (1:1000; Sigma) for 90 min. After rinsing in 0.1 M PBS for 30 min, the stain was visualized after reaction with 0.015% 3,3'-diaminobenzidine (Sigma) in phosphate buffer (pH 6.0, 0.1 M) containing 0.075% hydrogen peroxide. After six subsequent rinses in 0.1 M PBS, the sections were mounted onto gelatin-coated slides, air-dried, dehydrated in ascending concentrations of ethyl alcohol, cleared in xylene, and cover slipped with DPX mounting medium. As a negative staining control, sections were processed for immunohistochemistry with the primary antibody deleted. Immunoabsorption testing using these antibodies was recently reported by us.²⁷ All sections from all of the groups were processed at the same time with the same solutions in wire bottom trays, assuring that all tissues received similar exposure to all reagents. Stained sections were observed with a Nikon FXA microscope (Nikon, Melville, NY) linked to a Pentium PC (Intel, Santa Clara, CA) through an Optronics DEI-470 (Optronics, Goleta, CA) digitally enhanced color microscope video camera with built-in Digital Image Processor at $\times 10$ magnification. The average immunodensity was measured using the NIH image analysis software (Scion Corporation, Frederick, MD). The average intensity of staining of lamina I and II in five random sections from each animal was determined by outlining the laminar borders and comparing the density of immunostaining relative to measurements obtained for white matter, which was used as a reference point to normalize staining among sections.

Statistical Procedures

All data were expressed as mean $\pm$ SEM. Behavioral and immunohistochemical data were tested for statistical significance with repeated-measures analysis of variance with a significance level set at $P < 0.05$ to allow multiple comparisons between groups at different time points. *Post hoc* comparisons included Student paired and unpaired *t* tests to test statistical differences between control and experimental groups and before and after treatment comparison within the same group.

Results

Characterization of the Pancreatitis Model

To assess the inflammatory state of the pancreas, blood was drawn from the tail vein of Lewis rats treated either with DBTC or vehicle. Blood from animals in the naive group was also drawn for analysis. Serum was analyzed for pancreatic enzymes content (amylase and lipase). Rats with DBTC treatment had significantly elevated concentrations of amylase (fig. 1A) and lipase (fig. 1B) during the first week after tail vein injection. The steady increase of serum parameters in the DBTC group was not observed in the control groups.

Pancreatic samples taken from all rats were stained with hematoxylin and eosin and examined for evidence of inflammation. Figure 2A shows a histologic section from normal pancreas for comparison. Signs of acute pancreatitis included interstitial edema, moderate infiltration of neutrophilic granulocytes, and acinar atrophy (fig. 2B). As a control for specificity of the effects of DBTC, histologic samples from the liver were also examined. The hematoxylin– eosin staining for liver revealed no differences between control rats and rats treated with DBTC (figs. 2C and 2D, respectively). The abdominal wall and the internal organs were inspected visually at the end of the behavioral studies for presence of blue dye extravasation. No traces of blue dye were present on the abdominal wall or the other organs of the abdominal cavity. Extravasation was clearly evident, particularly associated with the head (duodenal portion) of the pancreas.

Behavioral Studies

Lewis rats, which had received a tail vein injection of DBTC, vehicle injection, or no manipulation, were tested at 1, 3, 7, 10, 14, and 21 days after injection. The observer performing the behavioral testing was blind to the animal's condition. The rats injected with DBTC demonstrated increased sensitization to mechanically applied stimuli on the abdominal area, *i.e.*, the number of withdrawals from the von Frey stimulation at different gram forces increased (fig. 3). The percentage of animals that responded by withdrawing from the von Frey filaments in more than 2 of 10 applications increased with the force of the filaments. Thus, the 204.1-mN von Frey filament evoked responses of greater than 2 in 100% of the rats. DBTC-injected rats tested for thermal reactivity demonstrated increased sensitivity to heat stimuli on days 3 and 7 after injection compared with naive and vehicle control groups and compared with their own baseline (fig. 4). The withdrawal latencies to heat stimuli for DBTC-injected animals were significantly different from their own baselines on days 1, 3, and 7 (fig. 4). Rats were also tested on additional days in between time points 3 and 7 (von Frey and thermal stimuli). On these additional days, rats also demonstrated nociceptive behaviors that were similar to the ones reported at 3 and 7 days (data not shown). The effects of DBTC were less in Lewis-inbred rats that were fed a soy meal diet (data not shown).

Effect of Morphine on Nociceptive Behavior

For this particular study, the nociceptive responses to each von Frey filament were summated to obtain one single index of responsiveness to mechanical stimulation and morphine treatment. Injection of morphine sulfate had an antinociceptive effect on those

animals that had developed pancreatitis and the behavioral changes described above. The antinociception produced was dose-dependent (fig. 5) but was highly significant with the 10-mg/kg dose of morphine. No changes in behavior of animals in control groups were evident for the three doses of morphine used.

Immunohistochemical Studies

The same animals used for behavioral studies were killed for immunohistochemical procedures to minimize the total number of rats in these studies. Spinal cord tissue (T6–T10) was sampled from animals 3, 7, 14, and 21 days after DBTC injection and from controls. Figure 6A shows a control section for SP staining. The experimental pancreatitis group showed increased relative staining density for SP (fig. 6B). CGRP staining showed no apparent changes in density by qualitative visual inspection (figs. 6C and 6D). Quantitation of the staining density showed that SP staining increased significantly on days 3 and 7 (fig. 7A). The CGRP staining did not increase significantly (fig. 7B).

Discussion

The current study tested the hypothesis that the Lewis inbred strain of rats treated with DBTC developed serum and behavioral changes consistent with persistent pancreatitis.^{8,12,13} Lewis rats expressing both behavioral and neurochemical changes exhibited clinical signs of pancreatitis during the first week (increased serum concentrations of amylase and lipase). Histologic signs of pancreatic inflammation were also observed during the first week. Inbred Lewis rats injected with DBTC developed increased cutaneous sensitivity demonstrated by an increase in withdrawals from von Frey fiber stimulation applied to the abdominal area as well as a decrease in thermal thresholds in the same region. Increased sensitivity in these measures may represent the “referred” cutaneous pain experienced by patients with pancreatitis. These behavioral changes were reversed by morphine dose dependently, suggesting that these behaviors were nociceptive related, as demonstrated in other studies where morphine attenuated similar pain-related indices.^{7,36–38} The abdominal area from which stimulations evoked these behaviors was confined to zones documented in humans to be referred areas for pancreatic pain. This is supported by concurrent findings that the inflammation was restricted to the pancreas. This includes the presence of inflammatory cells in the histologic sections and methylene blue plasma extravasation. The histologic findings were normal for the liver, and methylene blue extravasation was not evident for the liver and abdominal wall. If the abdominal wall had been involved, a more widespread sensitization might have been present. Animals that demonstrated behavioral changes also expressed an increase in staining density for SP in the superficial laminae of the T6–T10 spinal cord sections sampled. This region receives the majority of primary afferent fibers that innervate the pancreas.^{19,39}

Significant challenges have been encountered in attempts to develop animal models of pancreatic pain because of their acute nature and costly development.^{40–42} Some procedures creating pancreatitis are often invasive, introducing a number of extraneous experimental variables (abdominal surgery effects, behavioral inconsistencies, *etc.*).^{43,44} The visceral pain described here is reproducible and useful for comparison of intragroup and intergroup

relations and experimental conditions.⁴⁵ Many animal models of pancreatic pain use the induction of acute inflammation in the pancreas to establish changes in the periphery in the organ and dorsal root ganglia.^{5,46} These inflammatory models are short-lived or lead to multiorgan failure, and thus their utility for study of persistent changes in visceral pain transmission at the level of the spinal cord are limited. The development of an animal model of persistent pancreatic inflammation with central changes revealed through behavioral testing will be useful for assessing the utility of pharmacologic agents that may reduce visceral nociception. In the context of this animal model, persistent pancreatitis is considered an inflammatory episode that last more than 24–48 h, and thus it mimics one of the recurrent bouts of inflammation and abdominal pain experienced by patients with chronic pancreatitis, perhaps persisting because of ingestion of alcohol in our rats as in humans with chronic alcoholic pancreatitis. Clinical signs of pancreatitis in humans include increased serum concentrations of the pancreatic enzymes amylase and lipase plus a variety of other clinical signs.¹⁴ If a pancreatic biopsy is performed in patients, histologic signs of inflammation are present in the pancreas, including invasion by inflammatory cells, acinar atrophy, ruptured or engorged pancreatic ducts, and interstitial edema.⁴⁷ These same histologic signs of inflammation and enzyme concentration changes were seen in the pancreas of rats injected with DBTC.

Nociceptive behavioral reflex changes have been used in many studies as a reflection of the presence and extent of nociceptive changes in animals. Visceral pain is often “referred” to the abdominal dermatomes that receive their innervation from the same spinal segments that innervate the visceral organs.^{11,12,48} Pain originating specifically from the pancreas is often “referred” to the upper abdomen and radiates to the back.^{8,9} Measurements of nociceptive responses in a variety of experimental conditions have been used as valid quantitative methods to assess the equivalent of mechanical allodynia and thermal hyperalgesia in animal models.¹ In assessing visceral nociception, measurements of animal activity or pseudoaffective reflexes are often used.^{7,45} Laird *et al.*^{10,37} recently introduced the use of tests of cutaneous sensitivity to measure visceral nociception. In the current study we used a modified version of this method, quantifying a pseudoaffective reflex with supraspinal components (abdominal withdrawal and licking of the stimulated area after von Frey stimulation) as an index of evoked referred visceral pain. At the same time, thermal stimulation has been used to analyze the central sensitization induced by a variety of noxious manipulations.^{49–51} In our study, thermal stimulation was used to test the cutaneous zones of referred nociceptive sensitivity with pancreatitis and to establish the presence of central sensitization in response to visceral inflammation. Our results suggest that increases in nociceptive responsivity persist only during the period of pancreatic inflammation demonstrated histologically and with serum enzymes (between 3 and 7 days; figs. 1 and 3). When the inflammation subsides, the nociceptive behaviors return to baseline. In the highly inbred strain of rats used by Merkord *et al.*, it is reported that the pancreatitis persists through 6 months.^{31,52,53} The difference in duration of their model compared with the results of the current study is likely explained by their use of a highly inbred strain of rats, while we have attempted to repeat the results in the commercially available Lewis rat in which the pancreatitis and nociceptive behaviors persist for only the first 7–10 days. It is possible that the nociceptive behaviors we report here could also persist as chronic

pancreatic tissue becomes more fibrotic in the highly inbred model used by Merkord *et al.*³¹

While in humans with acute pancreatitis it is difficult to correlate inflammatory signs in the pancreas with abdominal pain, in the case of animal models with chronic pancreatitis, pain and histopathologic changes can be correlated.⁵⁴ In our model, the correlation between inflammation and increased nociceptive responses observed suggest that this persistent pancreatitis produced in commercially available rats can be used as a realistic model for this syndrome. These findings are consistent with previous studies reporting that inflammation of visceral tissue leads to states of increased pain.^{2,55} During the course of chronic pancreatitis in humans, patients can suffer from several relapsing flare-ups of silent or mildly symptomatic acute pancreatitis that is accompanied by abdominal pain.⁵⁶ The 7–10-day time course of the nociceptive increases in this study suggests that this model can be useful in mimicking the time course of a pancreatic flare-up in the human condition.

The neuropeptide alterations were investigated in this study because most visceral afferent fibers innervating the pancreas contain SP and CGRP, and alterations in the spinal cord of these neuropeptides would be indicative of central nociceptive changes. These peptides are known to undergo alterations in their expression during inflammatory conditions in the viscera.^{25,26,35,57,58} SP and CGRP have been shown to be involved in the maintenance of chronic pain conditions.^{23,59} Antagonists of the SP receptor (NK-1) can abrogate visceral pain responses.^{60,61} The NK-1 receptor is involved in the generation and maintenance of hyperalgesia,^{62,63} and its expression has been correlated with chronic pain states, including pain in chronic pancreatitis.⁶⁴ CGRP also plays a significant role in visceral nociception, and a synergistic action between SP and CGRP has been suggested based on the potentiation of SP-induced responses by CGRP.^{65–68} In our study, increased expression of SP immunoreactivity is observed at the same time points at which the animals with induced pancreatitis express nociceptive behaviors. The immunoreactivity for CGRP showed a trend to increase, but the increase did not reach statistical significance. These results suggest the involvement of SP in the maintenance of the pain state that develops after inflammation of the pancreas, and likely these central changes also contribute to the referred cutaneous nociceptive responses. A role for CGRP cannot be ruled out, however, in light of the ability of CGRP to maintain large intracellular stores and a different time course of dynamic changes.^{23,69} The increased expression of SP is perhaps an indication of peripheral nerve and central changes occurring in responses to increased afferent barrage from the inflamed pancreas and the resultant increased release of SP in the spinal cord.²⁷ At the same time, it is possible that the origin of increased expression of SP might not only be visceral afferents as the animals used for the immunohistochemical analysis also demonstrated increased sensitivity to somatic stimulation (mechanical von Frey and thermal stimulation). It has been demonstrated previously that short-term noxious stimulation can induce SP release in the spinal cord.⁷⁰ The persistent animal model described here has as an advantage, characteristics of longer-term inflammation, including indications of a sensitized state in the spinal cord that could lead to long-term changes.⁶ Sensitization of these animals to a second pancreatic insult or other noxious manipulations has not yet been attempted and would require further studies.

In conclusion, an animal model of persistent pancreatitis with a 1-week time course has been developed in commercially available rats that demonstrate nociceptive behavioral responses. These behaviors are responsive to morphine, which suggests that these behaviors are nociceptive-specific. Neuropeptide alterations in the spinal cord and the presence of altered nociceptive responses in referred cutaneous sites indicate an alteration of nociceptive processing in the central nervous system. These studies provide insight into the neurochemistry of this disease process at the spinal cord level and form the basis for further characterization and validation of this model for investigation of visceral nociceptive processing.

Acknowledgments

Supported by RO1 grant No. NS 39041 from the National Institutes of Health, Bethesda, Maryland.

References

1. Millan MJ. The induction of pain: An integrative review. *Prog Neurol.* 1999; 57:1–164.
2. Cervero F. Sensory innervation of the viscera: Peripheral basis of visceral pain. *Physiol Rev.* 1994; 74:95–138. [PubMed: 8295936]
3. Merriam LT, Wilcockson D, Samuel I, Joehl RJ. Ligation-induced acute pancreatitis increases pancreatic and circulating trypsinogen activation peptides. *J Surg Res.* 1996; 60:417–21. [PubMed: 8598679]
4. Schmidt J, Compton CC, Rattner DW, Lewandrowski K, Warshaw AL. Late histopathological changes and healing in an improved rodent model of acute necrotizing pancreatitis. *Digestion.* 1995; 56:246–52. [PubMed: 7544747]
5. Gaeta L, Dionigi G, Dionigi R. Experimental models of acute pancreatitis. *Chir Ital.* 2000; 52:469–97. [PubMed: 11190542]
6. Mayer AE, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. *Gastroenterology.* 1994; 107:271–93. [PubMed: 8020671]
7. Ness TJ, Randich A, Gebhart GF. Further behavioral evidence that colorectal distention is a 'noxious' visceral stimulus in rats. *Neurosci Lett.* 1991; 131:113–6. [PubMed: 1791969]
8. Graham, DD.; Bonica, JJ. Painful diseases of the liver, biliary system and pancreas. In: Loeser, JD.; Butler, SH.; Chapman, R.; Turk, DC., editors. *Bonica's Management of Pain.* 3. Philadelphia: Lippincott Williams & Williams; 2001. p. 1293-308.
9. Z'graggen, K.; Wilson, PG.; Neoptolemos, JP.; Buchler, MW. Diagnosis of acute pancreatitis: Clinical aspects. In: Beger, HG.; Warshaw, AL.; Buchler, MW.; Carr-Locke, DL.; Neoptolemos, JP.; Russell, C.; Sarr, MG., editors. *The Pancreas.* London: Blackwell; 1998. p. 466-71.
10. Laird JMA, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F. Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. *Neuroscience.* 2000; 98:345–52. [PubMed: 10854767]
11. Wesselmann U, Lai J. Mechanisms of referred visceral pain: Uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin. *Pain.* 1997; 73:309–17. [PubMed: 9469520]
12. Wesselmann U, Czakanski PP, Affaitati G, Giamberardino MA. Uterine inflammation as a noxious visceral stimulus: Behavioral characterization in the rat. *Neurosci Lett.* 1998; 246:73–6. [PubMed: 9627183]
13. Sigurdsson, GH. Necrotizing pancreatitis. Intensive-care measures. In: Beger, HG.; Warshaw, AL.; Buchler, MW.; Carr-Locke, DL.; Neoptolemos, JP.; Russell, C.; Sarr, MG., editors. *The Pancreas.* London: Blackwell; 1998. p. 508-20.
14. Uhl, W.; Vogel, R.; Z'graggen, K.; Buchler, MW. Diagnosis of acute pancreatitis: markers of pancreatic necrosis. In: Beger, HG.; Warshaw, AL.; Buchler, MW.; Carr-Locke, DL.;

- Neoptolemos, JP.; Russell, C.; Sarr, MG., editors. The Pancreas. London: Blackwell; 1998. p. 472-7.
15. Keast JR, De Groat WC. Segmental distribution and peptide content of primary afferent neurons innervating the urogenital organs and colon of male rats. *J Comp Neurol.* 1992; 319:615–23. [PubMed: 1619047]
 16. Sharkey KA, Sobrino JA, Cervero F. Evidence for a visceral afferent origin of substance P-like immunoreactivity in lamina V of the rat spinal cord. *Neuroscience.* 1987; 22:1077–83. [PubMed: 2446196]
 17. Sharkey KA, Sobrino JA, Cervero F, Varro A, Dockray GJ. Visceral and somatic afferent origin of calcitonin gene-related peptide immunoreactivity in the lower thoracic spinal cord of the rat. *Neuroscience.* 1989; 32:169–79. [PubMed: 2586748]
 18. Su HC, Bishop AE, Power RF, Hamada Y, Polak JM. Dual intrinsic and extrinsic origins of CGRP- and NPY- immunoreactive nerves of rat gut and pancreas. *J Neurosci.* 1987; 7:2674–87. [PubMed: 2442325]
 19. Sharkey KA, Williams RG, Dockray GJ. Sensory substance P innervation of the stomach and pancreas. *Gastroenterology.* 1984; 87:914–21. [PubMed: 6205934]
 20. Donaldson LF, Harmar AJ, McQueen DS, Seckl JR. Increased expression of preprotachykinin, calcitonin gene-related peptide, but not vasoactive intestinal peptide messenger mRNA in dorsal root ganglia during development of adjuvant monoarthritis in the rat. *Mol Brain Res.* 1992; 16:143–9. [PubMed: 1281253]
 21. Garret NE, Kidd BL, Cruwys SC, Tomlinson DR. Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of mono-arthritic rats: Comparison with changes in synovial substance P levels. *Brain Res.* 1995; 675:203–7. [PubMed: 7540928]
 22. Galeazza MT, Garry MG, Yost HJ, Strait KA, Hargreaves KM, Seybold VS. Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. *Neuroscience.* 1995; 66:443–58. [PubMed: 7477885]
 23. Hanesch U, Blecher F, Stiller RU, Emson PC, Schaible HG, Heppelmann B. The effect of a unilateral inflammation at the rat's ankle joint on the expression of preprotachykinin-A mRNA and preprosomatostatin mRNA in dorsal root ganglion cells: A study using non-radioactive in situ hybridization. *Brain Res.* 1995; 700:279–89. [PubMed: 8624722]
 24. Hanesch U, Pfrommer U, Grubb BD, Schaible HG. Acute and chronic phases of unilateral inflammation in rat's ankle are associated with an increase in the proportion of calcitonin gene-related peptide-immunoreactive dorsal root ganglion cells. *Eur J Neurosci.* 1993; 5:154–61. [PubMed: 8261097]
 25. Traub RJ, Hutchcroft K, Gebhart GF. The peptide content of colonic afferents decreases following colonic inflammation. *Peptides.* 1999; 20:267–73. [PubMed: 10422883]
 26. Roza R, Reeh PW. Substance P, calcitonin gene related peptide and PGE₂ co-released from the mouse colon: A new model to study nociceptive and inflammatory responses in viscera, in vitro. *Pain.* 2001; 91:213–9. [PubMed: 11514080]
 27. Lu Y, Westlund KN. Effects of baclofen on colon inflammation-induced FOS, CGRP and SP expression in spinal cord and brainstem. *Brain Res.* 2001; 889:118–30. [PubMed: 11166695]
 28. Vera-Portocarrero L, Lu Y, Westlund KN. Experimental pancreatitis induced by dibutyltin dichloride (DBTC): Behavioral and spinal neuropeptide alterations. *Soc Neurosci Abstr.* 2000; 26:932.
 29. Shir Y, Ratner A, Raja SN, Campbell JN, Seltzer Z. Neuropathic pain following partial nerve injury in rats is suppressed by dietary soy. *Neurosci Lett.* 1998; 240:73–6. [PubMed: 9486475]
 30. Sparmann G, Merkord J, Jaschke A, Nizze H, Jonas L, Lohr M, Liebe S, Emmrich J. Pancreatic fibrosis in experimental pancreatitis induced by dibutyltin dichloride. *Gastroenterology.* 1997; 112:1664–72. [PubMed: 9136846]
 31. Merkord J, Weber H, Jonas L, Nizze H, Hennighausen G. The influence of ethanol on long-term effects of dibutyltin dichloride (DBTC) in pancreas and liver of rats. *Hum Exp Toxicol.* 1998; 17:144–50. [PubMed: 9587782]
 32. Choy C, Yoon Y, Na H, Kim S, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. *Pain.* 1994; 59:369–76. [PubMed: 7708411]

33. Hulsebosch CE, Xu G-Y, Perez-Polo JR, Westlund KN, Taylor CP, McAdoo DJ. Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. *J Neurotrauma*. 2000; 17:1205–17. [PubMed: 11186233]
34. Bennet GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders in pain sensation like those seen in man. *Pain*. 1988; 33:87–107. [PubMed: 2837713]
35. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain*. 1988; 32:77–88. [PubMed: 3340425]
36. Giamberardino MA, Affaitati G, Lerza R, Vecchiet L. Pre-emptive analgesia in rats with artificial ureteric calculosis. Effects on visceral pain behavior in the post-operative period. *Brain Res*. 2000; 872:148–54. [PubMed: 10996145]
37. Laird JMA, Martinez-Caro E, Garcia-Nicas E, Cervero F. A new model of visceral pain and referred hyperalgesia in the mouse. *Pain*. 2001; 92:335–42. [PubMed: 11376906]
38. Yu YC, Koo ST, Kim CH, Lyu Y, Grady JJ, Chung JM. Two variables that can be used as pain indices in experimental animal models of arthritis. *J Neur Meth*. 2002; 115:107–13.
39. Won MH, Park HS, Jeong YG, Park HJ. Afferent innervation of the rat pancreas. Retrograde tracing and immunohistochemistry in the dorsal root ganglia. *Pancreas*. 1998; 16:80–7. [PubMed: 9436867]
40. Pap A, Boros L. Alcohol-induced chronic pancreatitis in rats after temporary occlusion of biliopancreatic ducts with ethibloc. *Pancreas*. 1989; 4:249–55. [PubMed: 2755945]
41. Freiburghaus AU, Redha F, Ammann RW. Does acute pancreatitis progress to chronic pancreatitis? A microvascular pancreatitis model in the rat. *Pancreas*. 1995; 11:374–81. [PubMed: 8532654]
42. Reber HA, Karanjia ND, Alvarez C, Widdison AL, Leung FW, Lutrin FJ. Pancreatic blood flow in cats with chronic pancreatitis. *Gastroenterology*. 1992; 103:652–9. [PubMed: 1634080]
43. Samuel I, Toriumi Y, Yokoo H, Wilcockson DP, Trout JJ, Joehl RJ. Ligation-induced acute pancreatitis in rats and opossums. A comparative morphologic study of the early phase. *J Surg Res*. 1994; 57:299–311. [PubMed: 8028340]
44. Houghton AK, Wang C-C, Westlund KN. Do nociceptive signals from the pancreas travel in the dorsal column? *Pain*. 2001; 89:207–20. [PubMed: 11166477]
45. Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus. Physiological and pharmacological characterization of pseudoaffective reflexes in the rat. *Brain Res*. 1988; 450:153–69. [PubMed: 3401708]
46. Toma H, Winston J, Micci M-A, Shenoy M, Pasricha PJ. Nerve growth factor is upregulated in the rat model of l-Arginine-induced acute pancreatitis. *Gastroenterology*. 2000; 119:1373–81. [PubMed: 11054396]
47. Kloppel, G.; Maillet, B. Histopathology of acute pancreatitis. In: Berger, HG.; Warshaw, AL.; Buchler, MW.; Carr-Locke; Neoptolemos, JP.; Russell, C.; Sarr, MG., editors. *The Pancreas*. London: Blackwell; 1998. p. 404-9.
48. Giamberardino MA, Valente R, De Bigontina P, Vecchiet L. Artificial ureteral calculosis in rats: Behavioural characterization of visceral pain episodes and their relationship with referred lumbar muscle hyperalgesia. *Pain*. 1995; 61:459–69. [PubMed: 7478690]
49. Ossipov MH, Lai J, Malan TP, Porreca F. Spinal and supraspinal mechanisms of neuropathic pain. *Ann NY Acad Sci*. 2000; 909:12–24. [PubMed: 10911921]
50. Shu XQ, Mendell LM. Neurotrophins and hyperalgesia. *Proc Natl Acad Sci U S A*. 1999; 96:7693–6. [PubMed: 10393882]
51. Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. *Proc Natl Acad Sci U S A*. 1999; 96:7687–92. [PubMed: 10393881]
52. Merkord J, Jonas L, Weber H, Kroning G, Nizze H, Hennighausen G. Acute interstitial pancreatitis in rats induced by dibutyltin dichloride (DBTC): Pathogenesis and natural course of lesions. *Pancreas*. 1997; 15:392–401. [PubMed: 9361094]
53. Merkord J, Weber H, Sparmann G, Jonas L, Hennighausen G. The course of pancreatic fibrosis induced by dibutyltin dichloride (DBTC). *Ann NY Acad Sci*. 1999; 880:231–7. [PubMed: 10415868]

54. Di Sebastiano P, Fink T, Weihe E, Friess H, Innocenti P, Bege HG, Buchler MW. Immune cell infiltration and growth-associated protein 43 expression correlate with pain in chronic pancreatitis. *Gastroenterology*. 1997; 112:1648–55. [PubMed: 9136844]
55. Ness TJ, Gebhart GF. Visceral pain: A review of experimental studies. *Pain*. 1990; 41:167–234. [PubMed: 2195438]
56. Mossner J. Diagnosis. In: Beger, HG.; Warshaw, AL.; Buchler, MW.; Carr-Locke, DL.; Neoptolemos, JP.; Russell, C.; Sarr, MG., editors. *The Pancreas*. London: Blackwell; 1998. p. 724–7.
57. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. *Am J Gastroenterol*. 1993; 88:908–13. [PubMed: 7684884]
58. Holzer P. Implications of tachykinins and calcitonin gene-related peptide in inflammatory bowel disease. *Digestion*. 1998; 59:269–83. [PubMed: 9693197]
59. Bennet AD, Chastain KM, Hulsebosch CE. Alleviation of mechanical and thermal allodynia by CGRP (8–37) in a rodent model of chronic central pain. *Pain*. 2000; 86:163–75. [PubMed: 10779673]
60. Julia V, Morteau O, Bueno L. Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distention in rats. *Gastroenterology*. 1994; 107:94–102. [PubMed: 7517374]
61. McLean PG, Garcia-Villar R, Fioramonti J, Bueno L. Effects of tachykinin receptor antagonists on the rat jejunal distention pain response. *Eur J Pharm*. 1998; 345:247–52.
62. Traub RJ. The spinal contribution of substance P to the generation and maintenance of inflammatory hyperalgesia in the rat. *Pain*. 1996; 67:151–61. [PubMed: 8895243]
63. Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, Finke MP, Li J, Lappi DA, Simone DA, Mantyh PW. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. *Science*. 1999; 286:1558–61. [PubMed: 10567262]
64. Shrikhande SV, Friess H, di Mola FF, Tempia-Caliera A, Conejo Garcia JR, Zhu Z, Zimmermann A, Buchler MW. NK-1 receptor gene expression is related to pain in chronic pancreatitis. *Pain*. 2001; 91:209–17. [PubMed: 11275376]
65. Plourde V, St-Pierre S, Quirion R. Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. *Am J Physiol*. 1997; 273:G191–6. [PubMed: 9252526]
66. Friese N, Diop L, Chevalier E, Angel F, Riviere PJ, Dahl SG. Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. *Reg Peptides*. 1997; 70:1–7.
67. Julia V, Bueno L. Tachykininergic mediation of viscerosensitive responses to acute inflammation in rats: Role of CGRP. *Am J Physiol*. 1997; 272:G141–6. [PubMed: 9038887]
68. Biella G, Panara C, Pecile A, Sotgiu ML. Facilitatory role of calcitonin gene-related peptide (CGRP) on excitation induced by substance P (SP) and noxious stimuli in rat spinal dorsal horn neurons. An iontophoretic study in vivo. *Brain Res*. 1991; 559:352–6. [PubMed: 1724408]
69. Sluka KA, Dougherty PM, Sorkin LS, Willis WD, Westlund KN. Neural changes in acute arthritis in monkeys. III. Changes in substance P, calcitonin gene-related peptide and glutamate in the dorsal horn of the spinal cord. *Brain Res Rev*. 1992; 17:29–38. [PubMed: 1379098]
70. Honore P, Menning PM, Rogers SD, Nichols ML, Basbaum AI, Besson J, Mantyh PW. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. *J Neurosci*. 1999; 19:7670–767. [PubMed: 10460273]

Fig. 1. Measurement of serum concentrations of amylase and lipase from naive, vehicle-injected, and dibutyltin dichloride (DBTC)-injected rats. (A) Time course of amylase serum concentrations through 3 weeks after tail vein injection. * $P < 0.05$ compared with vehicle-injected group. (B) Time course of lipase serum concentrations through 3 weeks after tail vein injection. * $P < 0.05$ compared with vehicle-injected group. Concentrations are expressed in units per liter. Error bars denote SEM.

Fig. 2. Paraffin sections of pancreas stained with hematoxylin and eosin from rats injected with dibutyltin dichloride (DBTC; 4- μ m sections). (A) Normal pancreas (from naive and vehicle-injected animals) were similar in appearance. (B) Pancreas 3 days after DBTC injection in the tail vein (8 mg/kg body weight). The pancreas shows acinar atrophy (*arrowhead*), stromal proliferation (*thick arrow*), and edema in the interlobular and intralobular ducts (*thin arrow*). (C) Liver tissue section from a control Lewis rat stained with hematoxylin and eosin. (D) Liver section from a Lewis rat injected with DBTC taken 7 days after injection. No signs of inflammation are apparent in the liver. Scale bar = 100 μ m.

Fig. 3.

Time course of nociceptive behaviors. The y-axis indicates the average number of reflexive withdrawals from von Frey stimuli applied to the abdominal surface of rats (AWE). (A) Rats with dibutyltin dichloride (DBTC) injection demonstrate a greater sensitivity to von Frey stimuli (4.86 mN) compared with naive and vehicle-injected animals at 3 and 7 days after DBTC injection. (B) Similar results were obtained with von Frey stimuli with an applied force of 9.96 mN. (C) Suprathreshold stimuli (von Frey 204.1 mN) also evoked greater reactivity from rats with DBTC injection compared with rats from the other groups. $+P < 0.05$ when comparing the respective animal group behavior to its baseline measure at time point 0. $*P < 0.05$ when compared with corresponding controls (naive and vehicle-injected groups). Error bars denote SEM.

Fig. 4.

Time course for the withdrawal latencies of rats injected with dibutyltin dichloride (DBTC), vehicle, or neither (naïve animals). Rats with DBTC injection demonstrated more rapid reflexive withdrawal to abdominal stimulation with a radiant heat source 3 and 7 days after injection compared with the vehicle-injected and naive groups. * $P < 0.05$ compared with vehicle control. + $P < 0.05$ compared with baseline (time point 0). Error bars denote SEM.

Fig. 5.

Dose-response curves for nociceptive responses to von Frey stimuli (cumulative scores) and heat stimuli at days 3 and day 7 after either saline or morphine systemic injection in animals treated previously with either vehicle (v) injection or dibutyltin dichloride (DBTC) injection. * $P < 0.05$ versus that group's own baseline (Student paired t test). + $P < 0.05$ comparing saline and morphine groups (Student unpaired t test). **,++ $P < 0.01$. (A) Day 3 responses to von Frey stimuli. (B) Day 3 responses to heat stimuli. (C) Day 7 responses to von Frey stimuli. (D) Day 7 responses to heat stimuli. AWE = average withdrawal event (the summation of responses to three von Frey filaments; see Methods). Error bars denote SEM.

Fig. 6. Representative photomicrographs of spinal cord sections showing staining for substance P (SP; *A* and *B*) and calcitonin gene-related peptide (CGRP; *C* and *D*) in the dorsal horn. (*A* and *C*) Sections taken from control animals; (*B* and *D*) sections taken from animals with pancreatic inflammation induced by tail vein injection of dibutyltin dichloride.

Fig. 7.

Time course for immunostaining density of substance P (SP) and calcitonin gene-related peptide (CGRP) in the superficial dorsal horn. (A) Quantitative immunohistochemistry demonstrates expression increases for SP at days 3 and 7 from animals injected with dibutyltin dichloride for comparison to the other groups ($*P < 0.05$). (B) The CGRP immunostaining showed a trend of increased density at all time points, but the increase did not reach statistical significance. Error bars denote SEM.